MELOXIVET® Oral solution

Analgesic and Anti-inflammatory.

Meloxivet®, Meloxicam 1 mg / mL, Oral solution, is indicated for the control of pain and inflammation associated with osteoarthritis symptoms in dogs.

Technical Specification



Dosage form

Oral solution

Therapeutic action

Analgesic and Anti-inflammatory.


Each mL of oral solution contains:
Meloxicam ........................................ 1 mg
Excipients q.s.p ............................... 1 mL


Meloxivet®, Meloxicam 1 mg / mL, Oral solution, is indicated for the control of pain and inflammation associated with osteoarthritis symptoms in dogs.

Mode of application

The solution must be administered using the dosing syringe included in the package, according to the weight of each animal. Administer mixed with a portion of food or directly into the dog's muzzle.

Route od administration and dosage

Oral administration.

Administer an initial dose of 0.2 mL for each kilo of weight on the first day of treatment, followed by a maintenance dose of 0.1 mL for each kilo of weight every 24 hours. These doses are equivalent to administering an initial dose of the active ingredient of 0.2 mg / kg of weight on the first day of treatment, followed by a maintenance dose of 0.1 mg / kg of weight every 24 hours.

The duration of treatment will depend on the condition to be treated. For acute pain, the duration of treatment can last up to 15 days depending on the degree of pain and inflammation. For chronic pain, the duration of treatment can be prolonged from 21 to 28 days. Both acute and chronic treatment should be discontinued after 10 days if there is no apparent improvement or if vomiting or occult blood occurs in the stool.

Drug interactions

  • Nonsteroidal anti-inflammatory drugs (NSAIDs) may reduce the effects of angiotensin-converting enzyme inhibitors (eg Enalapril, Benazepril) on blood pressure.
  • Meloxicam interacts with anticoagulants like Heparin or Warfarin and may increase the possibility of bleeding.
  • Its administration with corticosteroids or other NSAIDs could increase the risk of gastrointestinal toxicity (ulceration, bleeding, vomiting or diarrhea).
  • NSAIDs may reduce the diuretic effects of Furosemide.
  • NSAIDs may increase the risk of nephrotoxicity, when used in conjunction with nephrotoxic or diuretic drugs, such as Furosemide and aminoglycosides.


  • Meloxicam is contraindicated in dogs with known hypersensitivity to Meloxicam, Piroxicam or other NSAIDs.
  • Do not administer to dogs younger than 6 months or weighing less than 6 kilos.
  • Meloxicam should not be used in dogs with ulceration or active gastrointestinal bleeding.
  • Do not use in patients with liver, heart or kidney failure and bleeding disorders.
  • Do not administer to pregnant or lactating females or breeding animals.

Special precautions for the operator

  • En caso de contacto con la piel se recomienda lavar las manos con jabón y abundante agua.
  • En el caso de contacto con los ojos, lávese con abundante agua por 15 minutos. Si se desarrolla irritación y esta persiste, consultar al médico.
  • En caso de ingestión accidental, no inducir el vómito. Lave la boca con abundante agua. En caso de desarrollar irritación gástrica, obtener ayuda médica.


Special warnings and precautions for use:

  • Special care should be taken in dehydrated, hypovolemic, and hypotensive animals as there is an increased potential risk of developing kidney toxicity.
  • Treatment should be discontinued if the expected clinical response is not observed.
  • Keep out of the reach of children.

Adverse effects

  • Adverse effects reported in dogs treated with Meloxicam are similar to those observed with other NSAIDs and include gastrointestinal effects (vomiting, loss of appetite, loose stools, diarrhea, melena, gastrointestinal ulcerations, hematemesis), liver (elevated liver enzymes, jaundice), dermatological ( pruritus, urticaria, dermatitis), kidney (azotemia, creatinine and blood urea elevation, renal failure), central nervous system and behavior (ataxia, personality disorders, seizures, drowsiness, hyperactivity, depression, tremors and lethargy in puppies) and hematological (alteration in coagulation times, immunomediated hemolytic anemia, immunomediated thrombocytopenia).
  • The unwanted effects generally occur after 7 days of treatment and in most cases are transient in nature and disappear once treatment is complete. In the case of observing unwanted effects and / or adverse reactions, treatment should be suspended.


Special precautions for the disposal of unused product or waste material:
All unused medicine or the residues derived from it, must be disposed of in an environmentally safe way. Do not dispose of empty containers or containers with product residues in water courses. Do not throw away empty containers or containers with product residues along with household waste. Contact the manufacturing laboratory to receive instructions regarding the correct disposal.


Store at a temperature between 15 and 30 ° C, protected from light. Once opened, use the product within 30 days. Discard the unused product after that period of time.

Condition of sale

Sale with a Veterinary Medical prescription.


Bottle with 60 mL

Prepared by

Laboratorio Drag Pharma Chile Invetec S.A.


Chile: Reg. SAG Nº 2415
Perú: Registro. SENASA F.99.32.I.0130

Available for sale

Imported and Distributed in Peru by:
Representaciones Durand SAC.
Av. Manuel Olguín No. 501 Office No. 604 Santiago de Surco Lima.

You have entered drug info or veterinary products intended exclusively (s) kind (s) indicated (s).

Drag Pharma Lab is not responsible for the consequences of misuse of the products, and the use of this information without consulting a veterinarian